enGene, Inc. Announces Issuance of Core US Patent
3/11/2008 10:09:40 AM
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 10, 2008) - enGene Inc. announced today that the U.S. Patent and Trademark Office has issued US Patent 7,335,646, which grants enGene claim to a method to induce endocrine cells located in the gastrointestinal tract to synthesize and secrete different therapeutic proteins for the treatment of diabetes and obesity. This patent further strengthens enGene's position in using its Gut Endocrine cell Modification System (GEMS™) gene transfer technology to induce gut K-cells to produce insulin in a regulated fashion in subjects with insulin-dependent diabetes.
comments powered by